Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hESC-RPE Transplantation for Dry AMD
NCT02755428Phase 2Unknown
- Sponsor
- Chinese Academy of Sciences
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ASP7317 in age-related macular degeneration (AMD), sponsored by Chinese Academy of Sciences. Primary endpoint: Safety and tolerance of transplantation at 1 year. Status: unknown.
02
Drugs
ASP7317
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02755428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02755428.